Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: Post hoc analysis of a randomized, double-blind clinical trial

Annals of General Psychiatry

Volumn 10, Issue , 2011, Pages

  Alphs, Larry ^a   Bossie, Cynthia A ^a   Sliwa, Jennifer K ^a   Ma, Yi Wen ^b   Turner, Norris ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; NEUROLEPTIC AGENT; PALIPERIDONE; PLACEBO;

ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EJACULATION DISORDER; EXTRAPYRAMIDAL SYNDROME; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INJECTION SITE PAIN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; POST HOC ANALYSIS; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE;

EID: 79953767795     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/1744-859X-10-12     Document Type: Article

References (31)

1. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 2004, 161(Suppl):1-56.
2. Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003, 60:1228-1235. 10.1001/archpsyc.60.12.1228, 14662555.
3. Leucht S, Busch R, Hamann J, Kissling W, Kane JM. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 2005, 57:1543-1549. 10.1016/j.biopsych.2005.02.023, 15953491.
4. Glick ID, Bossie CA, Alphs L, Canuso CM. Onset and persistence of antipsychotic response in patients with schizophrenia. J Clin Psychopharmacol 2009, 29:542-547. 10.1097/JCP.0b013e3181befa2a, 19910718.
5. Kinon BJ, Chen L, Ascher-Svanum H, Stauffer VL, Kollack-Walker S, Zhou W, Kapur S, Kane JM. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-590. 10.1038/npp.2009.164, 19890258.
6. Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 2007, 68:818-825. 10.4088/JCP.v68n0601, 17592904.
7. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002, 63:892-909. 10.4088/JCP.v63n1007, 12416599.
8. Masand PS, Roca M, Turner MS, Kane JM. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review. Prim Care Companion J Clin Psychiatry 2009, 11:147-154. 10.4088/PCC.08r00612, 2736032, 19750066.
9. McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR. Use patterns for antipsychotic medications in medicaid patients with schizophrenia. J Clin Psychiatry 1999, 60:5-11. 10.4088/JCP.v60n0102, 10507275.
10. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010, 36:71-93. 10.1093/schbul/sbp116, 2800144, 19955390.
11. Bedford Laboratories Product information: Fluphenazine decanoate injection, USP, 25 mg/mL 2009, Bedford, OH: Bedford Laboratories, Bedford Laboratories.
12. Beresford R, Ward A. Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis. Drugs 1987, 33:31-49. 10.2165/00003495-198733010-00002, 3545764.
13. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008, 69:790-799. 10.4088/JCP.v69n0512, 18452346.
14. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003, 160:1125-1132. 10.1176/appi.ajp.160.6.1125, 12777271.
15. Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr Med Res Opin 2010, 26:377-387. 10.1185/03007990903482772, 20001492.
16. Janssen Product information: Invega® Sustenna® (paliperidone palmitate) 2010, Titusville, NJ: Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Janssen.
17. Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 2010, 13:635-647. 10.1017/S1461145709990988, 19941696.
18. Gopal S, Hough DW, Xu H, Lull JM, Gassmann-Mayer C, Remmerie BM, Eerdekens MH, Brown DW. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int Clin Psychopharmacol 2010, 25:247-256. 10.1097/YIC.0b013e32833948fa, 20389255.
19. Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, Kusumakar V, Yuen E, Palumbo J. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 2010, 30:235-244. 10.1097/JCP.0b013e3181dd3103, 20473057.
20. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010, 116:107-117. 10.1016/j.schres.2009.10.026, 19959339.
21. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, Washington, DC: American Psychiatric Association, 4, Text Revision, American Psychiatric Association.
22. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261-276.
23. Guy W. ECDEU Assessment Manual for Psychopharmacology (028 Clinical Global Impressions [CGI]) 1976, 218-222. Rockville, MD: National Institute of Mental Health.
24. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000, 101:323-329.
25. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970, 212:11-19. 10.1111/j.1600-0447.1970.tb02066.x, 4917967.
26. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989, 154:672-676. 10.1192/bjp.154.5.672, 2574607.
27. Guy W. ECDEU Assessment Manual for Psychopharmacology, revised 1976 (Abnormal Involuntary Movement Scale [AIMS]) 1976, 534-537. Rockville, MD: National Institute of Mental Health.
28. Davidson M, Emsley R, Kramer M, Ford L, Pan G, Lim P, Eerdekens M. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007, 93:117-130. 10.1016/j.schres.2007.03.003, 17466492.
29. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007, 90:147-161. 10.1016/j.schres.2006.09.012, 17092691.
30. Marder SR, Kramer M, Ford L, Eerdekens E, Lim P, Eerdekens M, Lowy A. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007, 62:1363-1370. 10.1016/j.biopsych.2007.01.017, 17601495.
31. Hough D, Lindenmayer JP, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1022-1031. 10.1016/j.pnpbp.2009.05.014, 19481579.